PAX2 Protein Induces Expression of Cyclin D1 through Activating AP-1 Protein and Promotes Proliferation of Colon Cancer Cells*
暂无分享,去创建一个
Hai-sheng Zhang | Li Fan | Jing Fang | B. Yan | Guo-Hao Wu | Bing Yan | Hai-Sheng Zhang | Xue-Bing Li | Li Fan | Yun-Fang Zhang | Guo-Hao Wu | Min Li | Jing Fang | Yunfang Zhang | Min Li | Xuebing Li
[1] M. Karin,et al. Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun , 1989, Cell.
[2] H. Iwao,et al. AP-1 and colorectal cancer , 2006, InflammoPharmacology.
[3] Andre C. Eaddy,et al. Inhibition of PAX2 expression results in alternate cell death pathways in prostate cancer cells differing in p53 status. , 2007, Cancer letters.
[4] C. Albanese,et al. The cyclin D 1 gene is a target of the b-catenin y LEF-1 pathway , 1999 .
[5] B. Spencer‐Dene,et al. JNK signalling modulates intestinal homeostasis and tumourigenesis in mice , 2009, The EMBO journal.
[6] Claus Scheidereit,et al. NF-κB Function in Growth Control: Regulation of Cyclin D1 Expression and G0/G1-to-S-Phase Transition , 1999, Molecular and Cellular Biology.
[7] M. Eccles,et al. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival , 2003, Oncogene.
[8] S. Reddy,et al. Role and regulation of activator protein-1 in toxicant-induced responses of the lung. , 2002, American journal of physiology. Lung cellular and molecular physiology.
[9] James R. Woodgett,et al. Phosphorylation of c-jun mediated by MAP kinases , 1991, Nature.
[10] Xianglin Shi,et al. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. , 2006, Carcinogenesis.
[11] J. Minna,et al. jun-B inhibits and c-fos stimulates the transforming and trans-activating activities of c-jun , 1989, Cell.
[12] B. Ruggeri,et al. PAX genes: roles in development, pathophysiology, and cancer. , 2007, Biochemical pharmacology.
[13] Frank McCormick,et al. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells , 1999, Nature.
[14] Zhao-dong Li,et al. Forkhead Transcription Factor FOXO3a Protein Activates Nuclear Factor κB through B-cell lymphoma/leukemia 10 (BCL10) Protein and Promotes Tumor Cell Survival in Serum Deprivation* , 2012, The Journal of Biological Chemistry.
[15] N. Coleman,et al. Colorectal cancer screening: prospects for molecular stool analysis , 2005, Nature Reviews Cancer.
[16] M. Eccles,et al. A PANorama of PAX genes in cancer and development , 2006, Nature Reviews Cancer.
[17] Duo Zheng,et al. Extracellular signal-regulated kinase 8-mediated c-Jun phosphorylation increases tumorigenesis of human colon cancer. , 2010, Cancer research.
[18] Axel Behrens,et al. Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development , 2005, Nature.
[19] M. Karin,et al. AP-1 as a regulator of cell life and death , 2002, Nature Cell Biology.
[20] Hai-sheng Zhang,et al. Prolyl hydroxylase domain protein 3 targets Pax2 for destruction. , 2011, Biochemical and biophysical research communications.
[21] M. Karin,et al. JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. , 1993, Genes & development.
[22] E. Bossy‐Wetzel,et al. Cell cycle‐dependent variations in c‐Jun and JunB phosphorylation: a role in the control of cyclin D1 expression , 2000, The EMBO journal.
[23] E. Wagner,et al. AP-1 in mouse development and tumorigenesis , 2001, Oncogene.
[24] H. Moch,et al. Loss of VHL and Hypoxia Provokes PAX2 Up-Regulation in Clear Cell Renal Cell Carcinoma , 2009, Clinical Cancer Research.
[25] C. Albanese,et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[26] Jing Fang,et al. Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. , 2010, Gastroenterology.
[27] M. Dyer,et al. The search for the retinoblastoma cell of origin , 2005, Nature Reviews Cancer.
[28] M. Eccles,et al. PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells. , 2006, Kidney international.
[29] J. Gnarra,et al. Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. , 1995, Cancer research.
[30] H. Mizuguchi,et al. Dominant-negative mutant of c-Jun gene transfer: a novel therapeutic strategy for colorectal cancer , 2004, Gene Therapy.
[31] H. Nishimatsu,et al. Transcriptional Activation of the cyclin D1 Gene Is Mediated by Multiple Cis-Elements, Including SP1 Sites and a cAMP-responsive Element in Vascular Endothelial Cells* , 2001, The Journal of Biological Chemistry.
[32] G. Landberg,et al. Expression of cyclin D1 and retinoblastoma protein in colorectal cancer. , 1998, European journal of cancer.
[33] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[34] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[35] M. Eccles,et al. In vivo validation of PAX2 as a target for renal cancer therapy. , 2008, Cancer letters.
[36] M. Eccles,et al. PAX2 suppresses apoptosis in renal collecting duct cells. , 2000, The American journal of pathology.
[37] C. Albanese,et al. Transforming p21ras Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions (*) , 1995, The Journal of Biological Chemistry.
[38] G. Landberg,et al. Human colorectal cancers with an intact p16/cyclin D1/pRb pathway have up-regulated p16 expression and decreased proliferation in small invasive tumor clusters. , 2000, The American journal of pathology.
[39] E. Wagner,et al. AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.
[40] Michael Karin,et al. Oncogene at last--c-Jun promotes liver cancer in mice. , 2003, Cancer cell.
[41] M. Bissonnette,et al. Elevated protein expression of cyclin D1 and Fra‐1 but decreased expression of c‐Myc in human colorectal adenocarcinomas overexpressing β‐catenin , 2002, International journal of cancer.
[42] N. Colburn,et al. AP-1 a target for cancer prevention. , 2007, Current cancer drug targets.
[43] H. Hibshoosh,et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. , 1996, Gastroenterology.
[44] P. Cassoni,et al. Role of Pax2 in Apoptosis Resistance and Proinvasive Phenotype of Kaposi's Sarcoma Cells* , 2004, Journal of Biological Chemistry.